Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab vs cetuximab in KRAS wild-type refractory metastatic colorectal cancer
CTR20160224Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in colorectal cancer (CRC), sponsored by Amgen. Started Aug 2016; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20160224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160224.